Filing Details

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
SCHEDULE 13G
(Rule 13d-102)
Information Statement Pursuant to Rules 13d-1 and 13d-2
Under the Securities Exchange Act of 1934
(Amendment No.       )*
	Adaptimmune Therapeutics PLC
(Name of Issuer)
	Ordinary shares, in the form of American Depositary Shares**
(Title of Class of Securities)
	00653A107
	(CUSIP Number)
	April 28, 2022
	(Date of Event Which Requires Filing of the Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨	Rule 13d-1(b)
x	Rule 13d-1(c)
¨	Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

** Each American Depository Share (“ADS”) represents 6 Ordinary Shares, par value £0.001 per share.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

CUSIP NO. 00653A107

13G

Page 2 of 10 Pages

 

1.	NAME OF REPORTING PERSON
	PFM Health Sciences, LP
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
	(a)       ¨
	(b)       x
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION
	Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER
		0
	6.	SHARED VOTING POWER
		54,658,680 ordinary shares1
	7.	SOLE DISPOSITIVE POWER
		0
	8.	SHARED DISPOSITIVE POWER
		See Row 6 above

9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	See Row 6 above
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	¨
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	5.8%2
12.	TYPE OF REPORTING PERSON
	IA; PN

 

 

1	Includes 54,685,680 Ordinary Shares of the issuer that are represented by 9,109,780 American Depositary Shares (“ADS”) directly held by the Funds. Each ADS represents 6 Ordinary Shares of the issuer.

 

2

The percentages reported in this Schedule 13G are based upon 941,191,902 ordinary shares outstanding as of April 19, 2022 (according to the issuer’s definitive proxy statement filed with the Securities and Exchange Commission on April 21, 2022). All of the other numbers and percentages reported in this Schedule 13G are as of 9:00 a.m. (ET) on the date of filing.

 

 

CUSIP NO. 00653A107

13G

Page 3 of 10 Pages

 

1.	NAME OF REPORTING PERSON
	PFM Health Sciences GP, LLC
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
	(a)       ¨
	(b)       x
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION
	Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER
		0
	6.	SHARED VOTING POWER
		54,658,680 ordinary shares
	7.	SOLE DISPOSITIVE POWER
		0
	8.	SHARED DISPOSITIVE POWER
		See Row 6 above

9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	See Row 6 above
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	¨
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	5.8%
12.	TYPE OF REPORTING PERSON
	OO

 

 

CUSIP NO. 00653A107

13G

Page 4 of 10 Pages

 

1.	NAME OF REPORTING PERSON
	Partner Asset Management, LLC
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
	(a)       ¨
	(b)       x
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION
	Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER
		0
	6.	SHARED VOTING POWER
		54,658,680 ordinary shares
	7.	SOLE DISPOSITIVE POWER
		0
	8.	SHARED DISPOSITIVE POWER
		See Row 6 above

9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	See Row 6 above
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	¨
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	5.8%
12.	TYPE OF REPORTING PERSON
	OO

 

 

CUSIP NO. 00653A107

13G

Page 5 of 10 Pages

 

1.	NAME OF REPORTING PERSON
	Brian D. Grossman
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
	(a)       ¨
	(b)       x
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION
	U.S. Citizen

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER
		0
	6.	SHARED VOTING POWER
		54,658,680 ordinary shares
	7.	SOLE DISPOSITIVE POWER
		0
	8.	SHARED DISPOSITIVE POWER
		See Row 6 above

9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	See Row 6 above
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	¨
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	5.8%
12.	TYPE OF REPORTING PERSON
	IN

 

 

CUSIP NO. 00653A107

13G

Page 6 of 10 Pages

 

Item 1(a)	Name of Issuer
	Adaptimmune Therapeutics PLC

 

Item 1(b)	Address of Issuer’s Principal Executive Offices
	60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, United Kingdom, OX14 4RX

 

Item 2(a)	Name of Person Filing
	This Schedule 13G is being jointly filed by PFM Health Sciences, LP (“PFM”), PFM Health Sciences GP, LLC (“PFM-GP”), Partner Asset Management, LLC (“PAM”), and Brian D. Grossman (“Grossman” and, collectively with PFM, PFM-GP, and PAM, the “Reporting Persons”) with respect to ordinary shares of the above-named issuer owned by PFM Healthcare Master Fund, L.P., a Cayman Islands limited partnership (“HCM”), and PFM Biotech Opportunities LP, a Delaware limited partnership (“BO” and, collectively with HCM, the “Funds”).

 

PFM is the investment advisor for the Funds. PAM is the general partner of the Funds. PFM-GP is the general partner of PFM and the manager of PAM. Grossman is the sole member of PFM-GP.

 

The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).

 

Item 2(b)	Address of Principal Business Office
	The address of the principal business office of each of the Reporting Persons is c/o PFM Health Sciences, LP, 475 Sansome Street, Suite 1720, San Francisco, California 94111.

 

Item 2(c)	Citizenship
	PFM is organized as a limited partnership under the laws of the State of Delaware. Each of PFM-GP and PAM is organized as a limited liability company under the laws of the State of Delaware. Grossman is a U.S. citizen.

 

Item 2(d)	Title of Class of Securities
	Ordinary shares, par value £0.001 per share

 

Item 2(e)	CUSIP Number
	00653A107

 

 

CUSIP NO. 00653A107

13G

Page 7 of 10 Pages

 

Item 3

If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

 

(a)

¨

Broker or dealer registered under Section 15 of the Exchange Act;

 

(b)

¨

Bank as defined in Section 3(a)(6) of the Exchange Act;

 

(c)

¨

Insurance company as defined in Section 3(a)(19) of the Exchange Act;

 

(d)

¨

Investment company registered under Section 8 of the Investment Company Act;

 

(e)

¨

An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

 

(f)

¨

An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

 

(g)

¨

A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

 

(h)

¨

A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

 

(i)

¨

A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

 

(j)

¨

A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);

 

(k)

¨

Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

 

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.

 

 

CUSIP NO. 00653A107

13G

Page 8 of 10 Pages

 

Item 4

Ownership

 

A.

PFM Health Sciences, LP, PFM Health Sciences GP, LLC and Partner Asset Management, LLC

 

(a)

PFM, PFM-GP and PAM may be deemed to beneficially own 54,658,680 ordinary shares.

 

(b)

The number of shares PFM, PFM-GP and PAM may be deemed to beneficially own constitutes approximately 5.8% of the ordinary shares outstanding.

 

(c)

Number of shares as to which such person has:

 

(i)

sole power to vote or to direct the vote: 0

 

(ii)

shared power to vote or to direct the vote: 54,658,680

 

(iii)

sole power to dispose or to direct the disposition of: 0

 

(iv)

shared power to dispose or to direct the disposition of: 54,658,680

 

B.

Brian D. Grossman

 

(a)

Grossman may be deemed to beneficially own 54,658,680 ordinary shares.

 

(b)

The number of shares Grossman may be deemed to beneficially own constitutes approximately 5.8% of the ordinary shares outstanding.

 

(c)

Number of shares as to which such person has:

 

(i)

sole power to vote or to direct the vote: 0

 

(ii)

shared power to vote or to direct the vote: 54,658,680

 

(iii)

sole power to dispose or to direct the disposition of: 0

 

(iv)

shared power to dispose or to direct the disposition of: 54,658,680

 

Item 5	Ownership of Five Percent or Less of a Class
	If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨.

 

Item 6	Ownership of More than Five Percent on Behalf of Another Person
	Not Applicable

 

Item 7	Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company
	See Item 2 above

 

 

CUSIP NO. 00653A107

13G

Page 9 of 10 Pages

 

Item 8	Identification and Classification of Members of the Group
	Not Applicable

 

Item 9	Notice of Dissolution of Group
	Not Applicable

 

Item 10	Certification
	By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

CUSIP NO. 00653A107

13G

Page 10 of 10 Pages

 

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

 

Dated this 9^th day of May, 2022.

 

PFM Health Sciences, LP			PFM Health Sciences GP, LLC
By:	PFM Health Sciences GP, LLC,		By:	/s/ Darin Sadow
	its general partner			Darin Sadow, Authorized Signatory
By:	/s/ Darin Sadow
	Darin Sadow, Authorized Signatory
PARTNER Asset MANAGEMENT, LLC			BRIAN D. GROSSMAN
By:	PFM Health Sciences GP, LLC,		By:	/s/ Darin Sadow
	its manager			Darin Sadow, attorney-in-fact*
By:	/s/ Darin Sadow
	Darin Sadow, Authorized Signatory

 

 

*

Darin Sadow is signing on behalf of Brian Grossman as attorney-in-fact pursuant to a power of attorney dated August 4, 2011, and incorporated by reference herein. The power of attorney was filed as an attachment to a filing by certain of the Reporting Persons on Schedule 13G for K-V Pharmaceutical Company on August 5, 2011.